Opyl is claiming credit for predicting a positive interim outcome of the $DXB/Dimerix ACTION3 Phase 3 trial of DMX-200 in FSGS Kidney Disease.
Bernice Averion, Medtech Marketing Marketing Manager of OPL's TrialKey business:
"...Opyl foresaw this success, predicting a high probability of 74.51% even before the official results were revealed.
"As a result, DXB's share price has experienced a notable surge, underlining the potential benefits of predictive tools like TrialKey for investors.
"Imagine having the foresight to spot viable investments before the market catches on!"
- Forums
- ASX - By Stock
- Opyl matters
Opyl is claiming credit for predicting a positive interim...
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
NEWS
Breakthrough programs slash healthcare events, driving a significant A$1.8M+ annual revenue boost
LU7
Discover the strong preliminary feasibility of the Bécancour Lithium Refinery, showcasing resilience in a low pricing environment and a strategic plan to capitalize on future price recoveries
Add OPL (ASX) to my watchlist
(20min delay)
|
|||||
Last
2.4¢ |
Change
0.001(4.35%) |
Mkt cap ! $4.097M |
Open | High | Low | Value | Volume |
2.4¢ | 2.4¢ | 2.4¢ | $2.384K | 99.33K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 50000 | 2.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.5¢ | 40003 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 50000 | 0.020 |
2 | 101192 | 0.017 |
4 | 2064325 | 0.016 |
3 | 261015 | 0.014 |
1 | 150000 | 0.012 |
Price($) | Vol. | No. |
---|---|---|
0.025 | 40003 | 1 |
0.030 | 500000 | 1 |
0.032 | 105961 | 1 |
0.033 | 233333 | 1 |
0.040 | 52254 | 1 |
Last trade - 15.35pm 04/10/2024 (20 minute delay) ? |
Featured News
OPL (ASX) Chart |